|
PANELISTS
Jianying Hu, Ph.D., is an IBM Fellow and Director of HCLS Research at IBM, where she also serves as Global Science Leader of AI for Healthcare. Dr. Hu joined IBM in 2003 after working at Bell Labs. She has over 30 years of experience conducting and leading research on machine learning, data mining, statistical pattern recognition, and signal processing applied to medical informatics, business analytics, and multimedia content analysis, with recent fucus on accelerated scientific discovery in health through scalable AI technologies.
Dr. Hu has published over 150 peer-reviewed scientific papers and holds 50 patents. She has served on numerous journal editorial boards and institutional advisory boards, and currently serves on the NASEM Committee on Establishing a Framework for Emerging Science, Technology and Innovation in Health and Medicine, and the External Advisory Board of the NIH AIM-AHEAD Program.
Dr. Hu is a fellow of the American College of Medical Informatics (ACMI), International Academy of Health Sciences Informatics (IAHSI), IEEE, and the International Association of Pattern Recognition (IAPR). In 2013, she received the Asian American Engineer of the Year Award.
Isaac Bentwich M.D., is the Founder and CEO of Quris-AI, an artificial intelligence innovator that is disrupting the drug development process, allowing pharma companies to develop safer drugs, faster. Bentwich is a physician and entrepreneur, who has previously founded and led two bio-AI technology companies that led revolutions in medicine and genomics.
Bentwich’s passion is leading inter-disciplinary teams of scientists and technologists to tackle impactful challenges in the intersection between machine-learning and life-sciences, and to leverage and commercialize these solutions.
One of the companies that Bentwich founded was Rosetta Genomics (NASDAQ:ROSG), which under his leadership analyzed the human genome, discovering hundreds of novel genes, more so than all the universities in the world combined, and delivered novel cancer diagnostics based on these genes. Its subsidiary, Rosetta Green (TASE:RSTG), was acquired by Monsanto for $35M.
As Envista’s founding CEO, Amir Aghdaei drives the company’s overall vision, dedicated to partnering with dental professionals to improve patient lives.
With over a decade of experience at Danaher, Envista separated from its parent company in 2019 via initial public offering, functioning now as an independent entity with a proven business system methodology, an experienced leadership team, and a strong culture grounded in customer centricity, innovation, respect, continuous improvement, and leadership.
Amir joined Danaher in October 2008 as Multi-Brand GM and VP of Fluke. He was named President of Tektronix in 2009, Group Executive in 2011, President of the Danaher Communications Platform and Danaher Russia in 2014, President of Dental Technologies in 2015, and President of Danaher’s Dental Platform in 2018. Prior to joining Danaher, Amir served as VP of Credence, and as GM and VP of the Measurement Systems Divisions of Agilent Technologies.
Amir holds a BS in Industrial Engineering from the Technology and Science University of Iran, an MS in Applied Mathematics and an MS in Computer Science from Georgia State University, and an MBA from the University of Delaware.
2022 STS forum Annual Meeting Sponsors
STS & AA-STS Members from the US
If you are interested in
becoming a Member, please contact AA-STS Secretary, Sachiko Oba-Cote
|
Prof. Hiroshi Komiyama, a prominent academic, scientist and engineer and leading authority in global sustainability, became Chairman of the Institute of Mitsubishi Research Institute, Inc. in April 2009, after completing four-year presidency as the 28th President at the University of Tokyo. He obtained a PhD in chemical engineering at the University of Tokyo. In 2010, he founded the 'Platinum Society Network' to achieve a sustainable society that solves environmental, aging, educational and economic issues. In 2017, he received the Sheikh Mohammed Bin Rashid Al Maktoum Knowledge Award (Knowledge Award) for his plan for solving social issues to create a better future for humanity, and acting as a driving force behind the effort to realize this vision, which he calls "Platinum Society." He was elected as the Chairman of the 
Dr. Hank McKinnell is the former chairman/CEO of Pfizer, the former chairman of Moody's, and co-founder of the Infectious Disease Institute, an organization dedicated to fighting infectious diseases in Africa by strengthening academic medical centers and building healthcare capacity through research, training, prevention, care, and treatment.
Hank joined Pfizer Inc. in Tokyo and over the years held positions of increasing responsibility around the world including serving as Chairman and CEO. Hank has served as the Chairman of Moody's Corporation and a Director of several life science companies.
Hank holds a Bachelor's Degree in business from the University of B.C., and M.B.A. and Ph.D. degrees from the Stanford University Graduate School of Business. Recipient Grand Cordon of the Order of the Rising Sun.
Dr. Bernard Meyerson is an IBM Fellow, and served as IBM’s first Chief Innovation Officer beginning in 2010. In 2013, his team integrated into IBM’s Corporate Strategy function, responsible for the definition and execution of corporate-wide technical and business initiatives. In 2019 he transitioned to Chief Innovation Officer Emeritus, continuing his work with key IBM Clients. He is also a Fellow of the American Physical Society and the Institute of Electrical and Electronics Engineers and a member of the National Academy of Engineering.
JIANYING HU, PH.D.
ISAAC BENTWICH, M.D.
AMIR AGHDAEI
